卵巢刺激和取卵后即刻与推迟行改良自然周期冻融胚胎移植的女性和男性伴侣心理社会与身体健康:一项随机对照试验的子研究
本研究为一项多中心随机对照非劣效性试验的子研究,纳入300名女性和228名男性伴侣,比较卵巢刺激和取卵后即刻与推迟行改良自然周期冻融胚胎移植的心理社会与身体健康。结果显示即刻组女性身体症状更多,但推迟组女性因等待时间而情绪受影响的比例更高,后者经多重检验校正后无统计学显著性。
要点
- 即刻组女性胃部和/或盆腔疼痛、腹胀、乳房肿胀或压痛的发生率显著高于推迟组。
- 推迟组女性因取卵到囊胚移植等待时间而情绪受影响的比例高于即刻组,但校正后无统计学显著性。
- 两组女性和男性伴侣的总体不孕相关压力或严重抑郁症状无显著差异,但女性普遍比伴侣更痛苦。
核心结论
- 即刻组女性报告的身体症状显著多于推迟组,而推迟组女性因等待时间情绪受影响的比例更高,但后者经多重检验校正后无统计学显著性。
研究设计与样本
- 一项正在进行中的多中心随机对照非劣效性试验的子研究,评估卵巢刺激和取卵后改良自然周期冻融胚胎移植的最佳时机。
- 参与者按1:1随机分配至卵巢刺激后即刻周期行改良自然周期冻融胚胎移植或后续周期行改良自然周期冻融胚胎移植。
- 基于首批受邀回答自评问卷的300名女性和228名男性伴侣的数据,数据收集时间为2021年4月至2024年3月。
主要发现
- 问卷应答率:即刻组女性90.3%、男性伴侣80.0%;推迟组女性82.3%、男性伴侣57.3%。
- 推迟组女性报告因取卵到囊胚移植等待时间而情绪受到一定程度或很大程度影响的比例高于即刻组(即刻组57.4% vs 推迟组73.9%,P=0.014),但多重检验校正后无统计学显著性(P=0.125)。
- 男性伴侣中未发现两组间对等待时间情绪反应的差异。
- 女性和男性伴侣中,即刻组与推迟组在总体不孕相关压力或严重抑郁症状方面均无显著差异,但女性普遍比其伴侣更痛苦。
- 即刻组胃部和/或盆腔疼痛(24.0% vs 9.4%,校正P=0.013)、腹胀感(33.8% vs 15.1%,校正P=0.010)和乳房肿胀或压痛(24.8% vs 0.9%,P<0.001)的发生率显著高于推迟组。
临床怎么用
- 作者认为,若即刻改良自然周期冻融胚胎移植被证明有效,身体和情绪因素可能在为个体患者选择治疗策略中起关键作用。
- 本研究显示即刻周期中与卵巢刺激相关的身体症状更多。
局限性
- 所有条目均为自报。
- 入组前未评估心理社会或身体健康状况。
- 男性伴侣样本量相对较小,女性伴侣因该组参与者数量极少而未纳入本子研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there differences in psychosocial and physical wellbeing among women and male partners undergoing modified natural cycle (mNC) frozen embryo transfer (FET) in immediate compared to postponed cycles after ovarian stimulation (OS) and oocyte pick-up (OPU)? SUMMARY ANSWER: Significantly more women in the immediate group reported physical symptoms than women in the postponed group whilst fewer were emotionally affected by waiting time, although the latter difference lost statistical significance after adjustment for multiple testing. WHAT IS KNOWN ALREADY: Infertility and fertility treatment are known to cause psychosocial distress in women and couples longing for a child. The treatment may be long-term and delayed for various reasons, such as the elective postponement of FET after a fresh transfer without pregnancy or an elective freeze-all cycle, possibly further increasing the level of distress. STUDY DESIGN, SIZE, DURATION: Sub-study of an ongoing multicentre randomized controlled, non-inferiority trial assessing the optimal timing for mNC-FET treatment after OS and OPU. Participants were randomized 1:1 to mNC-FET in the cycle immediately following OS or mNC-FET in a subsequent cycle. The study is based on data from the first women (N = 300) and male partners (N = 228) invited to answer a self-reported questionnaire assessing psychosocial and physical wellbeing. Data were collected from April 2021 to March 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: Questionnaires were distributed to all randomized women and their male partners on cycle day 2-5 of mNC-FET cycles and returned before the administration of ovulation trigger. The questionnaire consisted of validated items originating from the Copenhagen Multicentre Psychosocial Infertility-Fertility Problem Stress Scale (COMPI-FPSS) and Marital Benefit Measure (COMPI-MBM). Emotional reactions to waiting time in fertility treatment, mental health, general quality-of-life, and physical symptoms were also assessed. MAIN RESULTS AND THE ROLE OF CHANCE: Questionnaire response rates were 90.3% for women and 80.0% for male partners in the immediate group, and 82.3% for women and 57.3% for male partners in the postponed group. Approximately 90% of all women worried to some or a great extent about whether the treatment would be successful. More women in the postponed group reported that they were emotionally affected by the waiting time from OPU to blastocyst transfer to some or to a great extent (57.4% versus 73.9% in the immediate versus postponed group, P = 0.014), but the results were not significant after adjustment for multiple testing (P = 0.125). For male partners, no difference in emotional reactions to waiting time between groups was found. There was no significant difference in total infertility-related stress or symptoms of severe depression between the immediate and the postponed group for women or male partners, but women were generally more distressed than their partners. There was a significantly higher incidence of stomach and/or pelvic pain (24.0% versus 9.4%, adjusted P = 0.013), feeling of being bloated (33.8% versus 15.1%, adjusted P = 0.010) and swollen or tender breasts (24.8% versus 0.9%, P < 0.001) in the immediate group. LIMITATIONS, REASONS FOR CAUTION: All items were self-reported. No assessment of psychosocial or physical wellbeing was performed before participant enrolment. The sample size of male partners was relatively small, and female partners were not included in this sub-study due to a very small number of participants in this group. WIDER IMPLICATIONS OF THE FINDINGS: If immediate mNC-FET proves to be effective, physical and emotional factors may play a key role in choosing treatment strategy for the individual patient. This study demonstrated more physical symptoms related to OS in the immediate cycles. STUDY FUNDING/COMPETING INTEREST(S): The RCT was supported by Rigshospitalet's Research Foundation and an independent research grant from Merck A/S (MS200497_0024). Merck A/S had no role in the design of this study and will not have any role during its execution, analyses, interpretation of data, or decision to submit results. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors. A.P. received grants from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S and Cryos as payment to the institution. A.P. received consulting fees from IBSA, Ferring Pharmaceuticals, Gedeon Richter, Cryos and Merck A/S, and honoraria from Organon, Ferring Pharmaceuticals, Gedeon Richter and Merck A/S. A.P. received support for meeting attendance from Gedeon Richter. M.S. benefitted from a grant from Gedeon Richter. S.B. and C.C. benefitted from a grant from Merck A/S. S.B. is currently employed by Novo Nordisk. N.C.F. received grants from Gedeon Richter, Merck A/S and Cryos as payment to the institution. N.C.F. received consulting fees from Merck A/S and support for meeting attendance from Merck A/S, Ferring Pharmaceuticals, IBSA, and Gedeon Richter. N.C.F. is chair of the steering committee for the guideline groups for The Danish Fertility Society. E.L. received a radiometer contract on blood gas validation as a payment to the institution. E.L. received honoraria from Pfizer and support for meeting attendance from Astella. B.N. received grants from IBSA, Ferring Pharmaceuticals, Merck A/S, and Gedeon Richter as payment to the institution. B.N. received honoraria from Merck A/S and Organon and support for meeting attendance from IBSA and Gedeon Richter. B.N. and L.P. participate in an Advisory Board at Ferring Pharmaceuticals. L.P. received support for meeting attendance from Merck A/S, Ferring Pharmaceuticals, and Gedeon Richter. L.P. declare stocks in Novo Nordisk. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT04748874.
引用
- Bergenheim S, Saupstad M, Colombo C, et al. Psychosocial and physical wellbeing in women and male partners undergoing immediate versus postponed modified natural cycle frozen embryo transfer after ovarian stimulation and oocyte pick-up: a sub-study of a randomized controlled trial. Hum Reprod. 2025. PMID: 39673443. doi:10.1093/humrep/deae260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。